CTRI/2008/091/000086已完成2 期
A RANDOMIZED, OPEN LABELLED, CONTROLLED TRIAL OF A PROBIOTIC PREPARATION, VSL#3, FOR ASSESSING CLINICAL AND HISTOLOGICAL RESPONSE IN PATIENTS WITH MICROSCOPIC COLITIS
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age more than or equal to 18 years
- •2. Collagenous or lymphocytic colitis diagnosed on colon biopsies reviewed by a GI pathologist
- •3. Currently symptomatic as defined by more than or equal to 3 bowel movements per day with a stool consistency more than 3 and a diarrhea severity score more than 1 averaged over the week prior to enrolment in the study
- •4. A syndrome present for at least 8 weeks characterized by non-bloody watery diarrhea
- •5. A normal endoscopic appearance of the colonic mucosa
- •6. Colonic histopathology (that includes involvement of distal colon) consisting of excess mononuclear inflammatory cells in the lamina propria and surface epithelium without significant neutrophilic or eosinophilic inflammation, numerous crypts abscesses, or granulomata and no other evidence of Crohn?s disease
- •7. Eligible patients would be included if they had no steatorrhea, had taken no antibiotics or anti-inflammatory agents for at least 6 weeks and no antidiarrheals (e.g., Loperamide) for at least 2 weeks before beginning the study
- •8. Negative stool culture for pathogens (Salmonella and Shigella), parasites and ova/ cyst
- •9. For women of child-bearing potential, had a negative pregnancy test
- •10. Ability to give a valid informed consent.
排除标准
- •1. Unwilling or unable to give informed consent, follow protocol or to stop all medications used to treat diarrhea or colitis
- •2. Treatment with immunosuppressive medications or presence of an immunocompromised state
- •3. Other active diarrheal conditions (sprue, infection, hyperthyroidism)
- •4. Current infection with enteric pathogen
- •5. Significant hepatic, renal, endocrine (Diabetes), respiratory, neurological or cardiovascular disease as determined by the principal Investigator
- •6. Patient requiring hospitalization
- •7. Pregnancy or lactation
- •8. Use of any other investigational drug and/or participation in any clinical trial within 3 months of entry to this study
研究者
相似试验
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENTPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 17.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-DEDeutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen4,000
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE - ISAR-SAFEPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 14.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-ATDeutsches Herzzentrum Muenchen6,000
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE - ISAR-SAFEPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 14.1Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-DKDeutsches Herzzentrum Muenchen6,000
进行中（未招募）
不适用
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSAEUCTR2009-016377-15-ITIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
招募中
2 期
Efficacy of Virechana followed by Gomutra-haritaki in the fatty liver disease?CTRI/2021/11/038277AD